Comparative Pharmacology
Head-to-head clinical analysis: MYAMBUTOL versus POTASSIUM AMINOSALICYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYAMBUTOL versus POTASSIUM AMINOSALICYLATE.
MYAMBUTOL vs POTASSIUM AMINOSALICYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits arabinosyl transferase, an enzyme involved in cell wall synthesis of mycobacteria, leading to inhibition of cell growth.
Exact mechanism unknown; may competitively inhibit folic acid synthesis and/or disrupt mycobacterial cell wall metabolism via inhibition of salicylate hydroxylation.
15-25 mg/kg orally once daily (max 2.5 g/day); usual dose 20 mg/kg/day.
Adults: 4 g (as granules or powder) orally twice daily, equivalent to 8 g/day of aminosalicylic acid base.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 7-15 hours in renal impairment.
0.5-1.5 hours for parent drug; acetylated metabolite half-life 2-3 hours; accumulation occurs in renal impairment.
Renal: 50% unchanged drug; 20% as metabolite (ethambutol carboxylic acid); 15% as aldehyde intermediate; 15% unknown; fecal: <10%.
Renal: >80% as metabolites (acetyl, glycolyl conjugates) and unchanged drug; fecal: <5%.
Category C
Category C
Antitubercular Agent
Antitubercular Agent